Rogaine


Also found in: Dictionary, Thesaurus, Acronyms, Wikipedia.

minoxidil

Apo-Gain (CA), Gen-Minoxidil (CA), Loniten (UK) (CA), Minox (CA), Regaine (UK), Rogaine, Rogaine Extra Strength

Pharmacologic class: Peripheral vasodilator (direct-acting)

Therapeutic class: Antihypertensive, hair growth stimulant

Pregnancy risk category C

FDA Box Warning

• Drug may cause serious adverse effects (such as pericardial effusion occasionally progressing to tamponade) and may exacerbate angina pectoris. Reserve it for hypertensive patients who respond inadequately to maximum therapeutic doses of diuretic and two other antihypertensives.

• Give under close supervision, usually concurrently with therapeutic doses of beta blocker to prevent tachycardia and increased myocardial workload. Usually, drug also must be given with diuretic to prevent serious fluid accumulation. Patients with malignant hypertension and those already receiving guanethidine should be hospitalized when therapy begins so they can be monitored to avoid too rapid, or large orthostatic, blood pressure decreases.

Action

Reduces blood pressure by relaxing vascular smooth muscle, causing vasodilation. Action in hair growth stimulation unclear; vasodilatory action may enhance microcirculation around hair follicles.

Availability

Tablets: 2.5 mg, 10 mg

Topical solution: 2%, 5%

Indications and dosages

Severe symptomatic hypertension; hypertension associated with end-organ damage

Adults and children ages 12 and older: 5 mg/day as a single dose, increased carefully q 3 days. Usual range is 10 to 40 mg/day in single or divided doses. For rapid blood pressure control with careful monitoring, dosage may be adjusted q 6 hr. Maximum dosage is 100 mg/day.

Children younger than age 12: 0.2 mg/kg/day P.O. as a single dose. May increase in increments of 50% to 100% until blood pressure control is optimal. Usual range is 0.25 to 1 mg/kg/day; maximum recommended dosage is 50 mg/day.

Male-pattern baldness; diffuse hair loss or thinning in women; adjunct to hair transplantation

Adults: Apply 1 ml of 2% or 5% topical solution to affected area b.i.d. for 4 months or longer.

Alopecia areata

Adults: Apply 1 ml of 2% or 5% topical solution to scalp b.i.d.

Contraindications

• Hypersensitivity to drug or its components

• Dissecting aortic aneurysm

• Pheochromocytoma

Precautions

Use cautiously in:

• recent MI, malignant hypertension, heart failure, angina pectoris, severe renal impairment

• concurrent guanethidine therapy

• pregnant or breastfeeding patients.

Administration

• Give oral form with meals to decrease GI upset.

If patient is also receiving guanethidine, discontinue that drug 1 to 3 days before starting minoxidil, to avoid severe orthostatic hypotension.

• Know that oral form is usually given with a beta-adrenergic blocker or diuretic to control hypertension.

Adverse reactions

CV: ECG changes (such as T-wave changes), tachycardia, angina, pericardial effusion, cardiac tamponade, heart failure

GI: nausea, vomiting

Respiratory: pulmonary edema

Skin: hypertrichosis

Other: weight gain, edema

Interactions

Drug-drug. Antihypertensives, nitrates: additive hypotension

Guanethidine: severe orthostatic hypotension

Nonsteroidal anti-inflammatory drugs: decreased minoxidil efficacy

Drug-diagnostic tests. Alkaline phosphatase, blood urea nitrogen, creatinine, plasma renin activity, sodium: increased levels

Hematocrit, hemoglobin, red blood cells: decreased levels

Patient monitoring

• Monitor vital signs and ECG.

• Assess daily weight and fluid intake and output.

Monitor cardiovascular status carefully. Stay alert for signs and symptoms of heart failure.

• Watch for hypertrichosis.

• Know that hematologic and renal values usually return to pretreatment levels with continued therapy.

Patient teaching

• Instruct patient to take oral form with meals to decrease GI upset.

• Advise patient to weigh himself daily and report sudden gains.

• Tell patient taking oral form that drug may darken, lengthen, and thicken body hair. Tell him to shave or use depilatory to reduce unwanted hair growth. Reassure him that unwanted growth will disappear 1 to 6 months after he stops taking drug.

Instruct patient to immediately report difficulty breathing (especially when lying down) or pain in chest, arm, or shoulder.

• Teach patient how to use topical form. Urge him to read package insert carefully.

• Caution patient not to use topical form on other body parts and not to let it contact mucous membranes.

• Tell patient using topical form that new scalp hair will be soft and barely visible. Caution him to use only 1 ml twice daily, regardless of amount of balding. Remind him not to stop using drug suddenly, because new hair growth will be lost.

• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.

Rogaine

(rō′gān′)
A trademark for the drug minoxidil.

Patient discussion about Rogaine

Q. Is their a drug available to regain my energy back from having hypothyrodiam? I was diagnosed three years ago with Hypothyroidism. I have been using medication to level out my thyroid level. The lack of energy and weakness I am experiencing at the age of 42 is maddening. I want my life back the way it was. I am tired of feeling tired and zombie like.

A. Hormone replacement has to be continued throughout your life; Zoe is probably right: you may need a higher dose. Talk to your doctor about the fatigue, you should have regular check-ups again to monitor your hormone levels to get the right dosage.

You can always ask for more information about your condition: whether it's primary or secondary hypothyroidism and what may/may not have caused it, or what you can do to improve your symptoms.

More discussions about Rogaine
References in periodicals archive ?
For the 12 months ending February 2017, the annual sales of Women's Rogaine 5% minoxidil foam (minoxidil topical aerosol, 5% foam) were approximately USD20m, concluded the company.
What Ray doesn't realise is that the players had all clubbed together and coated the ball with Rogaine - the application that reverses baldness.
Converting Rogaine into an over-the-counter product instead of one available only by prescription requires FDA approval, and the management at Pharmacia & Upjohn Inc.
In early '96, Corvert, an antiarrhythmic drug, was approved in the U.S., as were OTC versions of the hair-growth stimulant Rogaine and the anti-smoking chewing gum Nicorette.
For example, pharmaceutical company Upjohn marketed its hair loss prevention product, Rogaine, via DRTV spots encouraging prospects to call for more information.
For example, hair-loss drug Rogaine now is sold over the counter, and I'm sure the company would like to know every hour how many stores have its product on the shelf.
In 1989 Lakeside Pharmaceuticals launched a multimedia advertising campaign for its Nicorette stop-smoking gum (Advertising Age, 1989a), and Upjohn, maker of Rogaine, a treatment to reverse hair loss, aired a 30-second TV commercial that urged viewers who suffer from hair loss to "see your doctor." This ad, however, did not mention the brand name due to FDA restrictions (Chicago Tribune, 1988).
And remember Rogaine? It turns out that this "cure" for baldness--which supposedly worries and embarrasses men as a visible sign of aging--didn't go over too well with men: It required too much effort, cost too much and didn't work very well.
Nobody knows how and why Rogaine works--when it does work.
Another hair trend among men applies to those with little or no hair, which, according to the website for Rogaine, is quite a lot.
In fact, TNT correspondent Charles Barkly made light of James' hair situation a few years ago on (https://www.youtube.com/watch?v=tpXU6vC8gm4#action=share) TNT's  "Inside The NBA." Barkley joked and proposed that James should try to seek a sponsorship deal with Rogaine to help ease his hair loss.
The impressive gains in sales of Rogaine since Johnson & Johnson (J&J) acquired the hair-growth formula nearly a decade ago are continuing: Data from IRI for the 52 weeks to April 19 show Rogaine sales at mass market outlets reached $74.1 million, more than double the annual total in 2006, the year the brand was bought from Pfizer Inc.